NK520 cell therapy for returning or hard-to-treat AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new cell therapy called NK520 for people whose acute myeloid leukemia (AML) has not responded to standard treatments or has returned after treatment. It aims to see if this treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have acute myeloid leukemia (a type of blood cancer) that has come back after treatment or hasn't gotten better after at least 2 different treatments.
- You are able to take care of yourself and do daily activities with little help.
- Your major organs (like kidneys, liver, heart, lungs) are working well.
- You do not have active infections like tuberculosis, HIV, syphilis, or uncontrolled hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
This early-phase study tests whether a treatment using NK cells plus monoclonal antibodies is safe and effective for adults with relapsed or hard-to-treat acute myeloid leukemia (AML). It’s mainly looking for safety, and whether the treatment can help control the leukemia.
This trial tests a natural killer (NK) cell therapy that targets a protein called CLL1 on leukemia cells. It aims to help people whose acute myeloid leukemia (AML) has come back or not responded to other treatments.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This trial tests a therapy made from your own immune cells, engineered to target a marker called CLL-1 on leukemia cells, for people whose AML has come back or hasn't responded to standard treatments.
This trial tests whether a special immune cell infusion (NK cells) from a half-matched family donor can help keep your AML in remission after initial chemotherapy. It is meant for people who have recently achieved their first remission and are otherwise healthy enough for a second round of chemo.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.